Deals
After $62 Billion Shire Win, Takeda CEO Faces More Headaches
- Takeda is completing deal with about $31 billion of loans
- Purchase gives it lucrative new drugs and bigger U.S. presence
This article is for subscribers only.
Takeda Pharmaceutical Co.’s Chief Executive Officer Christophe Weber navigated rebuffs, critics and a plunging stock price to win a $62 billion deal to acquire larger rival Shire Plc.
Integrating the Japanese drugmaker -- which began by selling herbal therapies 237 years ago -- with the sprawling American company will be even more complicated.